Tagged with COVID-19

USA During a panel discussion at the BIO International Convention, Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research (CBER) discussed the positive regulatory outcomes of the COVID-19 pandemic as well as the backlogs it created and the challenges of carrying the lessons learned forward.   At…

China A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric cancer partnership with CARsgen; Sino Biopharm’s continued attempt to buyout of F-star Therapeutics and Takeda’s deal with Hutchmed for a…

China A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial results, WuXi Biologics and GSK’s T-cell engager deal, Biocytogen and Hansoh’s antibody collaboration …   Pfizer CEO rules out generic…

Global Insights from US President Joe Biden’s chief medical adviser, Anthony Fauci, who served on the White House Coronavirus Task Force at the height of the pandemic, on the end of COVID-19, the danger of China’s recent surge in cases, preparedness for future pandemics, and the misinformation in the US that…

China A roundup of some of the biggest healthcare and pharma news from China, including the country’s struggle with a rampant COVID-19 outbreak and the external concern that surrounds it, China Meheco’s Paxlovid contract, Boston Scientific’s majority stake in Chinese medtech Acotec, Gracell Biotechnologies’ CAR-T therapy phase I trial 100 percent…

South Korea ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and medical aesthetics. He walks us through ExoCoBio’s exosome-based finished product line as well as its promising preclinical findings not just…

Global Due to lowered global demand, for the first time, Pfizer/BioNTech and Moderna are expected to see sales revenues for their COVID-19 vaccines take a major fall in Q2, but sales are expected to bounce back with jabs targeting new variants. According to Airfinity’s recent forecast, revenue for Pfizer/BioNTech’s vaccine will…

Global With the rise of more transmissible variants and the reduced efficacy of outpatient monoclonal antibody therapies, the market for oral antivirals is expected to climb to new heights this year. Pfizer to take the lead, followed by Merck, and possibly, Shionogi. According to Airfinity’s recent COVID-19 treatment revenue forecast, the…

Global At the recent Global Biopharma press briefing on COVID-19, held by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), industry leaders took on the issue of vaccine inequity, challenging the view that intellectual property waivers could be the answer. 13.7 billion doses of vaccines have been delivered and 11…

Roundup Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine.   AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership…

Covid-19 The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a Covid-19 drug, in South Africa this month. The company’s priority is ensuring access to vulnerable populations in emerging markets.     Cipla South Africa has been granted a license to manufacture and distribute remdesivir,…

Coronavirus Chinese biotech Clover Biopharmaceuticals may have flown under the radar thus far but it has stepped into the global limelight recently by partnering with GSK to develop a vaccine from the novel coronavirus, COVID-19, now wreaking havoc around the world. But who exactly are the brains behind Clover Biopharmaceuticals and…